Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials.

Human vaccines

Volumn 1, Issue 1, 2005, Pages 6-11

  Lee, Min Shi ^a   Walker, Robert E ^a   Mendelman, Paul M ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAINFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

AGE; CHILD; CLINICAL TRIAL; COST OF ILLNESS; ECONOMICS; HOSPITALIZATION; HUMAN; METHODOLOGY; PARAINFLUENZA VIRUS 3; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA VIRUS INFECTION; UNITED STATES; VIRUS INFECTION;

AGE FACTORS; CHILD; CLINICAL TRIALS; COST OF ILLNESS; HOSPITALIZATION; HUMANS; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 3, HUMAN; RESEARCH DESIGN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIROVIRUS INFECTIONS; UNITED STATES;

EID: 33750603900     PISSN: 15548600     EISSN: None     Source Type: Journal    
DOI: 10.4161/hv.1.1.1424     Document Type: Review

References (22)